Volume 56, Pages S28-S30 (July 1999)

Slides:

Advertisements

Similar presentations

Ischemic heart disease after renal transplantation

Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

End-stage renal disease in developing countries

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Bettina Haslinger-Löffler Kidney International

Lipopheresis in the nephrotic syndrome

My Approach to the Patient With Familial Hypercholesterolemia

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Membranous nephropathy: When and how to treat

Progression of renal failure and hypertensive nephrosclerosis

Gene electrotransfer: Potential for gene therapy of renal diseases

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Burden of chronic kidney disease: North Africa

Volume 58, Issue 1, Pages (July 2000)

Volume 85, Issue 3, Pages (March 2014)

Overcoming barriers that inhibit proper treatment of anemia

Volume 66, Pages S13-S17 (September 2004)

Abnormalities in lipoprotein metabolism in hemodialysis patients

Infection and chronic allograft dysfunction

Volume 62, Issue 5, Pages (November 2002)

Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson

Volume 70, Issue 11, Pages (December 2006)

Volume 74, Issue 5, Pages (September 2008)

Gary C.W. Chan, Sydney C.W. Tang Kidney International

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

The epidemiology of chronic kidney disease

Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: A role for CD44? Sandrine Florquin,

Edmund G. Lowrie Kidney International

Study of Heart and Renal Protection (SHARP)

Margus Annuk, Mihkel Zilmer, Bengt Fellström

Saulo Klahr, Jeremiah J. Morrissey Kidney International

Current Evidence for Perioperative Statins in Cardiac Surgery

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Macrophages and hypoxia in human chronic kidney disease

The central role of nuclear factor-κB in mesangial cell activation

Volume 61, Issue 1, Pages (January 2002)

Volume 76, Issue 4, Pages (August 2009)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

AGEs in foods: Do they play a role in uremia?

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Simvastatin in nephrotic syndrome

Calcium on trial: Beyond a reasonable doubt?

Volume 56, Pages S235-S237 (July 1999)

Volume 76, Issue 1, Pages 6-7 (July 2009)

Volume 73, Issue 9, Pages (May 2008)

Mediterranean diets: are they practical in the Western world?

Atherosclerotic nephropathy

Volume 72, Issue 2, Pages (July 2007)

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis Nosratola D. Vaziri, Tadashi Sato, Kaihui Liang

American Indian heritage and risk factors for renal injury

Effect of lipid-lowering strategies on tubular cell biology

Volume 69, Issue 10, Pages (May 2006)

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Volume 56, Pages S171-S173 (July 1999)

Arya M. Sharma, Joachim Beige, Armin Distler Kidney International

Ischemic heart disease after renal transplantation

Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Ellen G. Neven, Marc E. De Broe, Patrick.

Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status Kathryn J. Tinckam, Ognjenka Djurdjev, Alex.

Lipoprotein abnormalities in diabetic nephropathy

Volume 74, Pages S4-S9 (December 2008)

Alex B. Magil, Kathryn Tinckam Kidney International

Presentation transcript:

Volume 56, Pages S28-S30 (July 1999) Role of circulating lipid abnormalities in chronic renal allograft rejection Bertram L. Kasiske, M.D Kidney International Volume 56, Pages S28-S30 (July 1999) DOI: 10.1046/j.1523-1755.1999.07108.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Potential role of antilipemic therapy in chronic allograft rejection. 3-Hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors may decrease low density lipoprotein cholesterol levels, which, in turn, could theoretically increase free cyclosporine A (CsA) levels. CsA could reduce intimal damage by inhibiting T lymphocytes. Antioxidants could reduce the formation of oxidized low-density lipoprotein and thereby reduce foam cell formation. Abbreviations are: LDL, low-density lipoprotein; MP, macrophage. Kidney International 1999 56, S28-S30DOI: (10.1046/j.1523-1755.1999.07108.x) Copyright © 1999 International Society of Nephrology Terms and Conditions